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The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per
German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the
new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current
EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA
and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.
A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics
researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input
on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.
Distinctive features of registration trials in oncology need to be considered when these studies form basis
for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive
therapeutic options available post-progression. Ethical committees, caregivers and patients often demand
cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation
of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e.,
progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance
to patients.
Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance,
endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge
and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative
medicines in oncology.
JEL codes: D61; H51; I18.
Keywords: AMNOG; German health care reform; Oncology; Endpoints; Progression-free survival; Patient-relevant benefitIntroduction
Problem statement
Due to the severity of oncological diseases, pivotal stud-
ies in oncology are subject to special methodological
characteristics that must be taken into account during
the interpretation of the results. For ethical reasons, not
every study design that is theoretically possible can be
implemented in practice [1]. The European authorities* Correspondence: peter_kaskel@msd.de
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2014(European Medical Agency, EMA), the higher federal
authorities in Germany (Bundesinstitut für Arzneimittel
und Medizinprodukte, BfArM, and Paul-Ehrlich-Institute,
PEI, respectively) and ethics-committees in charge have
defined specific requirements in this respect [2-4]. The
benefit-assessment of a therapy in terms of reimbursement
issues should also take into account these specific pre-
requisites as part of the early-benefit-assessment (EBA), as
conducted by German HTA (i.e., Institute for Quality and
Efficiency in Health Care, IQWiG) as commissioned by the
Federal Joint Committee (G-BA), or G-BA itself for orphan
drugs). Assessments conducted based on the endpoint ofan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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patients at a disadvantage [5]. This position paper demon-
strates the basic positions of the authors in this regard,
especially in terms of patient-relevant endpoints (PRE) in
clinical trials.
Task force process
A task force to further evaluate endpoints in oncological
diseases, and survival endpoints in particular, under the
auspices of the German Association of Research-based
Pharmaceutical Companies (vfa) was appointed. Members
were experienced German outcomes research, medical,
health technology assessment (HTA) and biostatistics re-
searchers in industry. In a first step, after definition of
topics of interest, and text structure, respectively, author-
teams were assigned (i) to further evaluate endpoints in
oncology; (ii) to provide an integrated view on HTA, regu-
latory, medical and patients’ view; (iii) to further evaluate
clinical value of survival without disease getting worse (i.e.,
progression-free survival, PFS); and (iv) to review HTA
decisions on oncologic products in Germany. After
structured literature research had been performed and
draft versions on the pre-defined text topics had been
created, manuscript was shortened and a final inte-
grated structure of the manuscript was consented in a
face-to-face meeting. Afterwards, a second draft was
prepared, and input solicited from a panel of reviewers
from industry and external stakeholders. Input obtained
during a poster presentation at the European Meeting
of the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) in Berlin on Nov-6th,
2012 (PCN 152) was incorporated into the final version
of the manuscript. In a last step, an approval of the
final version was obtained from all authors.
Review
Marketing authorization (MA) of oncologic agents and
clinical considerations
MA procedures for new pharmaceuticals in oncology re-
view the therapeutic benefit:
The MA of a new pharmaceutical and/or the exten-
sion of the indication of an already approved drug are
strictly regulated legally and at various levels. All national
European regulatory agencies (including the BfArM and
PEI) and the EMA demand proof of efficacy and safety
resulting in a positive benefit-risk-ratio, and the clinical
trial results must be submitted for each pharmaceutical.
How clinical trials are conducted is stipulated in the
German Medicinal Products Act, [3] and the higher EU
directive 2001/20/EU, [6] respectively. Furthermore, a large
number of international and European guidelines as part
of the MA procedure must be heeded [2].
The situation of oncological patients–and also the aims
of a clinical trial–is marked by great heterogeneity:The categories for characterizing this heterogeneity in
oncology are [7]:
 curative–palliative
 palliative: different disease stages
 palliative: symptomatic-asymptomatic
 palliative: very different median life expectancy of
months (pancreatic cancer) to decades (indolent
lymphoma)
 palliative: well treatable (breast cancer: more than 10
approved pharmaceuticals) vs. non-treatable
Clinical trials in oncology, which represent the basis
for MA of pharmaceuticals, must take into account
the fact that the patients typically suffer from life-
threatening diseases. For ethical reasons and due to
medical needs, a new therapy that has not yet been fully
investigated in terms of efficacy and safety is often tested
first on patients with advanced disease for whom the
established therapies have failed [8]. Among the end-
points of the studies based on which efficacy is measured,
OS is recognized as the most important endpoint [9]. At
the same time, however, the determination of OS to
evaluate the effect of a therapy often hits ethical limits
and in many situations it is impossible or only possible in
limited fashion for methodological reasons (e.g. due to
different active follow-up therapies [10,11]). This is illus-
trated by several examples:
Oncological diseases with a long survival time: In
part, the analysis of OS requires long follow-up mon-
itoring periods, which delay the development of additional
effective substances or make the implementation of
clinical trials impossible, because in some cases the
endpoint can only be reached after many years or de-
cades. For example, chronic myeloid leukemia (CML) is
a disease for which survival benefits can only be esti-
mated through long-term evaluations after more than a
decade [12]. The same may apply for a new pharma-
ceutical for metastasized breast cancer [13]. Due to the
long survival time, an extension of OS could theoretic-
ally be proven through studies many years after launch.
However, this will not be possible in practice, because
it can be problematic to retain a sufficient number of
patients in randomized clinical trials over longer pe-
riods of time, and long-term follow-up data are evalu-
ated with caution among HTA researchers [14,15].
This particularly applies to oncological diseases for
which multiple therapy-options are used sequentially.
In these cases, survival is influenced by subsequent
therapies, which makes it more difficult to judge the ef-
fect of the pharmaceutical substance used first on the OS
endpoint. At a minimum it dilutes any effect [16]. Exam-
ples include metastasizing entities such as breast- and lung
cancer [17,1].
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an integrated view
The selection of the primary endpoint in clinical trials in
oncology and the cross-over question (Table 1) are typic-
ally the subject of intense discussion between researchers,
study groups, regulatory bodies and ethics commit-
tees. The EMA has defined specific endpoints that are ac-
ceptable from a regulatory standpoint in its “Guideline
on the evaluation of anticancer medicinal products in
man” [2]. With regard to survival time, the regulatory
agencies will demand OS as a primary endpoint if the
substance to be tested is probably more toxic than the
comparator, if no accepted therapies are available for
further treatment and if the time from disease progres-
sion to death is short. If a different endpoint is chosen,
this must be justified in detail to the regulatory agen-
cies. In this context, survival of patients without their
disease getting worse (i.e., PFS) is recognized as a clin-
ically valid endpoint for survival and will represent an
acceptable primary endpoint in the eyes of the regula-
tory agencies e.g. if subsequent therapies have an im-
pact on OS [2]. Outcomes for PFS in cancer patients
are available more quickly than for OS, and are not influ-
enced by additional therapies after disease progression.
Besides PFS, Disease-free survival (DFS) is regarded by
the regulatory agencies as an appropriate endpoint to
evaluate adjuvant therapies [2]. Other endpoints such as
“complete remission” (CR) are recognized in the treat-
ment of oncological diseases, the endpoint “objective
response rate” (ORR) is used e.g. for brain tumors. Typic-
ally, in these situations OS must also be captured (as a
secondary endpoint) with the objective that the new ther-
apy does not create a disadvantage in this respect [2].
Considerations made by the regulatory agencies based on
medical and scientific criteria and the endpoints of the
pivotal clinical trials, which have been specified before-
hand, must also be comprehensively taken into accountTable 1 Clinical trials for which ethics commissions, physician
of switching to the therapy of the other study arm
• A considerable efficacy advantage compared to the standard therapy ca
• A considerable efficacy advantage is demonstrated in an interim analysi
getting worse (i.e., progression-free survival, PFS).
• The decision to switch typically is being made at the individual patient
◦ As soon as a benefit in terms of the efficacy of the tested substa
treated with the new therapy.
◦ For ethical reasons, this must therefore be made possible, even i
◦ No trial participant can be asked to be treated with an inferior th
better therapy more clearly apparent in terms of overall survival
• Even if a trial does not provide for a cross-over, e.g. because the superio
their trial participation at any time in order to be treated with the new m
similar pharmaceuticals.
◦ Even this unplanned cross-over influences the survival time analyand recognized during the EBA by G-BA or IQWiG (if
commissioned by G-BA). Currently, this is not the case
(Additional file 1: Table S1).
Apart from OS, especially PFS must be mentioned
with regard to mortality. If these endpoints – agreed upon
with the regulatory agencies for assessing the benefit of a
new therapy–are not considered accordingly, as part of the
EBA, an assessment of the additional benefit can hardly be
achieved in an appropriate manner.
An improvement in terms of morbidity is also consid-
erably relevant for the patients:
Pursuant to the German Social Code, [18] insured
patients are entitled to treatment, if it is necessary to
diagnose a disease, cure it, prevent it from worsening or
alleviate its symptoms. Oncological treatments often
achieve an improvement in health state that is limited in
time, but this improvement does not necessarily mani-
fest itself in an extension of OS. Insured patients in
Germany are also entitled to treatment, if it provides
relief from their suffering. Currently, during EBA in
Germany as performed by G-BA and IQWiG using
HTA methodology, the treatment of tumor entities is
predominantly held up to the standard criteria of a cure
(without assigning any ratings) in terms of improved
mortality, alleviation of symptoms (morbidity) and an im-
provement in the patients‘ health related quality of life
(HRQoL; Figure 1). However, many diseases in oncology
have no curative treatment in the foreseeable future.
This includes e.g. advanced non-small cell lung cancer
(NSCLC), renal cell carcinoma (RCC) and some malig-
nant hematological diseases. Any HTA assessment con-
ducted based on the endpoint of OS alone would lead to
results that put the patients at a disadvantage within the
context of EBA in Germany [5]. Although the levels of
patient-relevant benefit (PRB) of EBA have been defined
(Table 2), it must be emphasized that a definition of the
term “patient relevance” and a final weighting of endpointss and patients demand cross-over designs, i.e. the option
n be expected for the substance to be tested
s e.g. with regard to a benefit in survival of patients without their disease
level.
nce compared to the comparator becomes apparent, patients wish to be
f and especially if the survival time analysis is influenced by it.
erapy until the end of his or her life, only to make the superiority of the
(OS).
rity of the new therapy is still uncertain, trial participants can terminate
edication (e.g. if it is already approved for another indication) or with




Improvement in health state
Shortening of illness
Extension of survival
Reduction of side effects
Improvement of HRQoL
Appropriate Comparator*
Appropriate in the therapeutic area  
(according to the generally acknowledged 
state of medical knowledge) 
Authorized for the indication (if a drug)
Preferably: Endpoint-tested; GBA-
confirmed patient-relevant benefit; 
reference-priced
Intervention
Figure 1 Key AMNOG terms, as per German Social Code (Book V). *or indirect comparison; **or validated surrogate. AMNOG=
Arzneimittelmarktneuordnungsgesetz (National health care law). HRQoL=Health related quality of life. G-BA=German Joint Federal Committee.
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the relevance of endpoints for patients can be incorporated
more strongly in EBA in the future. In this respect to
the set-up of treatment guidelines, both clinical experts
appointed by clinical professional societies and affected pa-
tients should be consulted in order to achieve a large de-
gree of acceptance in society.
Survival of patients without their disease getting worse
(PFS) is suitable as an endpoint in many oncological
therapies, not just for survival but–apart from other
target variables such as tumor response or the duration
of tumor response–also as a morbidity-related, separate
endpoint. A significant improvement of PFS with accept-
able side effects demonstrates a clinically relevant, valid
PRB in terms of morbidity (defined as the problems and
complications of a disease) especially in maintenance
treatment and palliative situations. In RCC, for example,
in the context of disease progression, not only new me-
tastases can occur, but also already existing metastases
can progress [19,20]. Last but not least, the (perhaps notTable 2 Levels of patient-relevant benefit, as per German Soc
1 Major (“erheblich”)–Lasting major improvement
–Especially recovery from the disease, a significant extension in the duration
of serious side effects
2 Important (“beträchtlich”)–Significant improvement
–Especially a reduction of serious symptoms, a moderate extension of the du
a relevant avoidance of serious side effects, or a significant avoidance of oth
3 Slight (“gering”)–Moderate and not just minor improvement
–Especially a reduction of non-serious symptoms of the disease or a relevant
4 Existing; but not quantifiable
–Because the scientific data basis does not allow such quantification
5 None
6 Smaller than the benefit of the appropriate comparatorresectable) primary tumor can deteriorate further. This
can be associated with symptoms and may require proce-
dures that directly burdens the individual patient [21,22].
PFS per se is of immediate, clinically and patient-relevant
value in these patients [23]. Furthermore, the patient can
be bothered by fear of progression. In contrast to irrational
fears, fear of progression is real and is apperceived by the
individual patients: Herschbach and colleagues have dem-
onstrated that in about one third of patients are distressed
or highly distressed due to fear of progression [24]. Finally,
the importance of progression for the patients has also
been demonstrated by Cella and Colleagues who found
a relatively stable course of HRQoL during progression-
free treatment period, and a dramatic decline in case of
progression [25].
Practical relevance: the case of imatinib and its implications
The practical relevance of such an approach is shown by
the case of imatinib for treatment of CML. Today, imatinib
is indisputably considered a breakthrough innovation inial Code
of survival, long-term freedom from severe symptoms or extensive avoidance
ration of life, an alleviation of the disease that is noticeable for the patients,
er side effects
avoidance of side effects
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MA based on PFS data.
In the pivotal trial for imatinib, [26] a significant
benefit for imatinib compared to the standard ther-
apy (interferon-alpha + cytarabine) was proven for an
overall population of 1,106 patients after 19 months in
terms of PFS. In the case of non-response to treatment
with the standard therapy, a cross-over to imatinib was
possible.
In retrospect, the cross-over in the International Ran-
domized Study of Interferon and STI571 (IRIS) study
also showed the innovative potential of imatinib: [26].
One trend for an OS benefit (post-hoc, p = 0.075) could
only be demonstrated for imatinib vs. standard therapy
through long-term evaluations after six years of follow-
up by Hochhaus and Co-workers [27]. For the German
Society for Hematology and Oncology (DGHO), Ehninger
and Wörmann further demonstrated that for this study
population during a six year time period, about 332 add-
itional patients would have died in the comparative arm
alone, had they been denied a cross-over to imatinib [28].
For ethical reasons alone, OS must not be the sole
valid endpoint for EBA of anticancer medicines. In the
case of the breakthrough innovation imatinib, if OS
would have been accepted as the only PRE, the drug
may have only been reimbursed after six years of avail-
ability in the German market. For NSCLC, patients are
often treated with an individualized, marker-based treat-
ment approach with medicines that received MA via a
primary PFS endpoint. In this indication, an increase of
OS rates has also been reported, confirming the positive
trend PFS had previously shown [29].
Apart from PFS, the parameters of (duration of ) tumor
response to therapy should be taken into account during
the evaluation of patient relevance in case regulatory au-
thorities have accepted these endpoints during evalu-
ation of benefit-risk ratio.
The disappearance, shrinkage or stabilization of a
tumor is also associated with a direct benefit for the
patient in many indications (such as lung cancer), e.g.
based on (i) Reduction or at least stabilization of tumor-
related symptoms (e.g. shortness of breath, congestion/
compression due to the tumor); [30] (ii) Delay of sub-
sequent treatment with additional side effects; [31]
(iii) Stabilization of the disease, as experienced positively
by the patient (“treatment is effective”) [32] and (iv) Possi-
bility of surgical intervention or improvement of the result
of surgery (e.g. neo-adjuvant treatment concept for invasive
mamma carcinoma) [33]. In addition, patient surveys
for e.g. NSCLC showed that in the progression of an
advanced disease the relevance of tumor and symptom
control is becoming more important and that therapy for
improving tumor symptoms is desired, even if an extension
of survival can no longer be achieved [34].Other PRE for morbidity include time to treatment
failure or cytogenetic complete remission rate. It must
also be considered that progression of a tumor disease is
typically associated with a deterioration of the general
condition and/or the disease-related symptoms, which
requires a change in therapy. A large number of pub-
lications are concerned with the aspect of the direct
influence of non-mortality-related parameters on the sub-
jective, patient-experienced disease situation [35-40].
IQWiG recently also followed the argument that
complete remission is also patient-relevant as an ultimate
target-variable in hematologic malignancies if it coincides
with less morbidity or improved HRQoL [41]. The authors
believe that a broad perspective must be applied to the
endpoints of oncological studies and the chosen endpoints
from the clinical trial should be recognized in the EBA in
individual cases. PFS in terms of a morbidity parameter
and other disease-related endpoints also constitute valid
PREs for EBA and must be used appropriately and com-
prehensively. Otherwise, EBA according to the state of sci-
ence and in compliance with the Volume V of the German
Social Code would be impossible for many oncological
pharmaceuticals.
It should be mentioned, that the value of study-
endpoints for the affected patients can be attained
through evaluation of patient preferences. For the ma-
lignant disease of plasmocytoma/multiple myeloma,
Mühlbacher and Nübling were able to demonstrate that,
apart from the effect of a treatment, patients in conjoint-
analyses rate other endpoints as equally important for
their subjective disease experience [42]. These preferred
factors, from a total of 16 polled endpoints, included pri-
marily a long-lasting effect of the therapy, disease-free
duration of life and therapy breaks. Noteably, these three
latter endpoints are weighted more strongly by the pa-
tients than an extension of OS alone. In order to meet this
explicit patient wish, it is indispensable that PFS as a mor-
bidity parameter must be viewed as imminently useful and
valuable to the affected patient. Guidances or recommen-
dations set up by relevant scientific societies need to be
taken into account in the benefit assessment.
Summary
In summary, for proving an additional PRB in oncology,
morbidity endpoints must be considered in addition to
mortality and HRQoL in order to adequately address the
complexity of the situation of the individual patient and
his or her treating physicians (see Figure 2).
In principle, these endpoints must be viewed on a par
according to the German Social Code. A gradation of
the PRB, depending on whether or not a gain in OS was
proven, is logically untenable, since the possibility of the
proof itself–as described–depends in many cases on the
tumor entity, the tumor stage and the individual
European authorities,
German federal authorities &
Ethical review committees
Definition of specific requirements
Planning and conduct of
registration trials in
oncology
These requirements have to be considered byIQWiG/G BA
Figure 2 Task force position flow chart.
Dabisch et al. Health Economics Review Page 6 of 82014, 4:2
http://www.healtheconomicsreview.com/content/4/1/2situation of the patient and not just on the pharmaceut-
ical alone. In this context, it must be emphasized once
more that a definition of the term “patient relevance”
and a final weighting of endpoints is still pending. As a
consequence, it must also be discussed how the rele-
vance of endpoints for the patient can enter EBA more
strongly in the future. Apart from clinical experts, the
affected patients in particular should also be consulted
in this respect. In accordance with the development of
treatment guidelines, both, clinical experts appointed by
clinical professional societies, and affected patients
should be consulted in order to achieve a large degree of
acceptance in society.
A close review of the individual case is necessary in
the operationalization of the PRB. While the G-BA’s wish
for a standardized assessment is understandable, the ex-
ample of imatinib for the treatment of CML [26-28]
illustrates nonetheless that the model currently under
discussion would not have properly assessed even a
recognized/established breakthrough innovation as such.
Conclusions
Depending on tumor entity and tumor stage, the end-
points for a PRB are not necessarily identical. In this re-
spect, all parties involved match in their statements.
EBA must not result in a loss of perception of the
disease-and stage-specific therapy needs based on meth-
odological simplification. Apart from endpoints assessing
survival time such as OS and PFS, endpoints regarding
morbidity in terms of symptoms and complications of a
disease as well as HRQoL also represent endpoints for
PRB in pivotal studies, are recognized by regulatory
agencies and must also be accepted in principle for EBA.
Apart from that, clinical-scientific findings and guidelines
as well as patient needs must be considered appropriately
and comprehensively.
The basic benefit of a new cancer therapy is proven
during the MA procedure and represents the basis of the
MA decision [2]. Therefore, as part of the EBA, the aspects
of clinical research and international regulatory MA ex-
perience must be incorporated in order to avoid a separate
German way. As a result, a broad and comprehensive
discussion with scientific experts as part of the EBA is
needed. This should help to avoid the emergence of de-
mands or the representation of opinions that miss themark regarding the needs of today’s society and specifically
the reality of medical research. Not taken into account in
this respect are ethical aspects of clinical research and the
needs of the patients.
If this path is not taken, new developments and thera-
peutic approaches in oncology in Germany would be faced
with unsubstantiated obstacles regarding the early benefit
assessment, which cannot be in the society’s interest.
Additional file
: Table S1. Outcomes of German HTA early benefit
assessments in Oncology, 2011-2013 (all oncological appraisals with at
least oral G-BA hearing before Apr-1st, 2013 included).
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